Philip Van Damme
Philip Van Damme is an expert in Neurology at Universitair Ziekenhuis Leuven (Belgium). As of November 2026, ScienceLeadR ranks Philip Van Damme in the top 1% of experts worldwide for Amyotrophic Lateral Sclerosis and Proteostasis Deficiencies. Philip Van Damme has authored 480 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 8 of them ongoing. SLR score: 1,525 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Genetics - Psychiatry - Neurosurgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2005 - 2026
Number : 480
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Global best practice recommendations for genetic counselling and testing in amyotrophic lateral sclerosis. PMID 42945473 — research design, sclerosis, genes, genetic testing, laboratories, amyotrophic lateral sclerosis, neurology | Brain | 2026 | 0 |
| 18F FDG-PET correlates of motor neuron disease motor variants. PMID 42262849 — sclerosis, neurons, motor neurons, positron-emission tomography, fluorodeoxyglucose f18, amyotrophic lateral sclerosis, motor neuron disease | Amyotroph Lateral Scler Frontotemporal Degener | 2026 | 0 |
| Sleep disturbances and respiratory dysfunction in amyotrophic lateral sclerosis. PMID 42214007 — sclerosis, sleep, amyotrophic lateral sclerosis, arousal, vital capacity, spine | Amyotroph Lateral Scler Frontotemporal Degener | 2026 | 0 |
| Conceptualizing cognition and behaviour across amyotrophic lateral sclerosis and frontotemporal dementia. PMID 42720086 — sclerosis, dementia, frontotemporal dementia, cognitive dysfunction, signs and symptoms, amyotrophic lateral sclerosis, neurology, cognition | Brain | 2026 | 1 |
| Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. PMID 42716044 — sclerosis, safety, amyotrophic lateral sclerosis, enzymes, nervous system | Lancet Neurol Top journal | 2026 | 1 |
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 23
Ongoing Clinical Trials
8 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS) 2025-524002-16-00 — sclerosis, safety, amyotrophic lateral sclerosis | Phase 3 | Recruiting | 2026 |
| A Phase 1 2 Study of the Safety and Tolerability of ICM VTx 002 in participants with ALS 2025-522697-37-00 — sclerosis, safety, amyotrophic lateral sclerosis | Phase 1/Phase 2 | Not yet recruiting | 2026 |
| A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) 2024-512536-29-00 — sclerosis, amyotrophic lateral sclerosis | Phase 2 | Active not recruiting | 2025 |
| A Master Protocol (OLMP) A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS) NCT07571200 — sclerosis, safety, amyotrophic lateral sclerosis, therapeutics | Phase 1 | Recruiting | 2026 |
| A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis NCT07571174 — sclerosis, safety, amyotrophic lateral sclerosis | Phase 1 | Recruiting | 2026 |
LeadR Networks
Main global connection map